Biomarin prepares for European approval of Ascendis competitor

US firm Biomarin has upgraded its financial expectations based on Q2, and is preparing a new drug that will challenge the existing market.
The EMA HQ in Amsterdam. | Photo: Rob Acket/EMA
The EMA HQ in Amsterdam. | Photo: Rob Acket/EMA
BY CHRISTOPHER DUE KARLSSON, TRANSLATED BY CATHERINE BRETT AND CHRISTOFFER ØSTERGAARD

US biotech firm Biomarin ended the second quarter with a revenue growth of 17 percent compared to the same period last year. The result was USD 501.7m.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading